Finasteride in the treatment of Taiwanese men with androgenetic alopecia: A 12-month open-label study

Kaohsiung Journal of Medical Sciences

Volumn 18, Issue 8, 2002, Pages 379-385

  Lin, Jeng Hsien ^a   Chen, Wen Chieh ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Alopecia androgenetica; Finasteride

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HAIR GROWTH; HAMILTON SCALE; HUMAN; LIVER DYSFUNCTION; MALE; MALE TYPE ALOPECIA; PATIENT CARE; PHOTOGRAPHY; QUESTIONNAIRE; SELF EVALUATION; TAIWAN; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALOPECIA; ENZYME INHIBITORS; FINASTERIDE; HUMANS; LIVER; MALE; PROSTATE-SPECIFIC ANTIGEN;

EID: 0036704455     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hamilton JB. Patterned loss of hair in man: Types and incidence. Ann N Y Acad Sci 1951;53:708-28.
2. Tosti A, Camacho-Martinez F, Dawber R. Management of androgenetic alopecia. J Eur Acad Dermatol Venereol 1999; 12:205-14.
3. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79:703-6.
4. Andersson S, Bishop RW, Russell DW. Expression cloning and regulation of steroidal 5α-reductase, an enzyme essential for male sexual differentiation. J Biol Chem 1989;264:16249-55.
5. Jenkins EP, Andersson S, Imperato-McGinley J, et al. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992;89:293-300.
6. Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993;92:903-10.
7. Bayne EK, Flanagan J, Einstein M, et al. Immunohistochemical localization of types 1 and 2 5α-reductase in human scalp. Br J Dermatol 1999;141:481-91.
8. Liang T, Heiss CE, Cheung AH, et al. 4-Azasteroidal 5αreductase inhibitors without affinity for the androgen receptor. J Biol Chem 1984;259:734-9.
9. Liang T, Rasmusson GH, Brooks JR. Biochemical and biological studies with 4-aza-steroidal 5 α-reductase inhibitors. J Steroid Biochem 1983;19:385-90.
10. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999;41:550-4.
11. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihidrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-8.
12. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39:578-89.
13. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999;40:930-7.
14. Norwood OT. Male pattern baldness: Classification and incidence. South Med J 1975;68:1359-65.
15. Takashima I, Iju M, Sudo M. Alopecia androgenetica: Its incidence in Japanese and associated conditions. In: Orfanos CE, Montagna W, Stüttgen G, eds. Hair Research: Status and Future Aspects. New York: Springer-Verlag, 1981:287-93.
16. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996;14:713-21.
17. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: Review of available data. J Urol 1996;155:3-9.
18. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6.